The global hemostasis testing systems market is expected to be worth US$ 3,518.1 million in 2032, growing at a 5.5% CAGR. The rising blood loss from large injuries caused by accidents and other external factors is driving the global hemostasis testing systems market. Furthermore, hemostatic agents are primarily used to treat wounds that have bled as a result of minor injuries. In 2022, the market is expected to be worth $2,059.6 million USD. The market expanded at a 4.8% annual rate between 2016 and 2021.
FMI, in its business report, elaborates the historical and current scenario of the global Hemostasis Testing Systems Market in terms of production, consumption, volume, and value. The report scrutinizes the market into various segments, regions and players on the basis of demand pattern and growth prospects.
Crucial information and forecast statistics covered in the Hemostasis Testing Systems market report will arm both existing and emerging market players with necessary insights to craft long-term strategies as well as maintain business continuity during a crisis such as the ongoing COVID-19 pandemic.
COVID-19 Impact Analysis on Hemostasis Testing Systems Market
The recent outbreak of the COVID-19 has turned the spotlight on the healthcare industry, and subsequently impacted the Hemostasis Testing Systems market. Severe shortages of critical medical supplies and a rapid rise in number of COVID-19 cases have resulted into a revolution rather than evolution in the healthcare ecosystems. Consequently, the impact is noticeable in the Hemostasis Testing Systems market.
Following government’s measures, particularly social distancing norms and stay-at-home orders, doctors are delaying or postponing elective surgeries unless critical to prevent the spread of the virus to individuals with comorbidities or chronic conditions. Additionally, movement restrictions and supply chain disruptions have created a logistical nightmare for market players, leading to severe product shortages in the global marketplace.
The FMI’s report includes an interesting chapter on preliminary impact of the COVID-19 on the Hemostasis Testing Systems market. This allows both leading and emerging market players to understand the market scenario during a crisis and aids them in making sound decisions to gain a distinct competitive edge.
Read More Details@ https://www.futuremarketinsights.com/reports/hemostasis-testing-systems-market
Hemostasis Testing Systems Market: Segmentation
Valuable information covered in the FMI’s Hemostasis Testing Systems market report has been segregated into key segments and sub-segments.
Hemostasis Testing Systems Market by Application Type:
- Hemophilia in Hemostasis Testing Systems
- Von Willerbrand Disease in Hemostasis Testing Systems
- Acquired Bleeding Disease in Hemostasis Testing Systems
Hemostasis Testing Systems Market by End Use Type:
- Hemostasis Testing Systems in Hospitals
- Hemostasis Testing Systems in Academic Institutions
- Diagnostics Laboratories in Hemostasis Testing Systems
Key players covered in the report include:
- Werfen
- Medtronic
- Siemens Healthcare GmbH
- Haemonetics Corporation
- Roche Diagnostics Limited
- Sysmex
- Abbott Laboratories
- Others
According to research report the coagulation analyzers market is projected to reach USD 4.84 billion by 2021 from USD 2.98 billion in 2016, at a CAGR of 10.2% from 2016 to 2021.The coagulation analyzers market is consolidated in nature due to the presence of a few large players.
The prominent players in the coagulation analyzers market include are Siemens AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Roche Diagnostics (Switzerland), Alere Inc. (U.S.), Sysmex Corporation (Japan), Nihon Kohden Corporation (Japan), Diagnostica Stago (France), Helena Laboratories (U.S.), Instrumentation Laboratory (U.S.), and International Technidyne Corporation (U.S.).Read More: https://www.marketsandmarkets.com/PressReleases/hemostasis-coagulation-analyzer.aspSiemens AG was the largest player in the global coagulation analyzers market, with a share of 24.7% in 2015.
In August 2016, Siemens launched the Sysmex CS-2500 System, a new mid-volume coagulation analyzer.
Moreover, in April 2016, Siemens and Sysmex extended their long-standing global agreement in hemostasis testing.
These developments significantly impacted the company's revenue and customer base.Thermo Fisher Scientific, Inc. (U.S.) was the second-largest player in the coagulation analyzers market, with a market share of 13.3% in 2015.
For instance, in October 2014, Thermo Fisher Scientific established a 350,000-square-foot manufacturing facility in California, U.S.
